(Q53743754)

18 May 2018

title

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group. (English)

1 reference

18 May 2018

1 reference

A Ferguson

1

1 reference

18 May 2018

M Campieri

2

1 reference

18 May 2018

W Doe

3

1 reference

18 May 2018

T Persson

4

1 reference

18 May 2018

G Nygård

5

1 reference

18 May 2018

language of work or name

English

0 references

publication date

1 February 1998

1 reference

18 May 2018

Alimentary Pharmacology & Therapeutics

published in

1 reference

18 May 2018

volume

12

1 reference

18 May 2018

issue

2

1 reference

18 May 2018

page(s)

175-183

1 reference

18 May 2018

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00285.X

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00285.X

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00285.X

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00285.X

Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00285.X

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00285.X

10.1046/J.1365-2036.1998.00285.X

21 January 2018

Identifiers

DOI

1 reference

18 May 2018

1 reference

18 May 2018